TABLE 3.

Characteristics of the 186 patients with ESBL-BSIs

CharacteristicsNo. (%)a of patients with BSI caused by:P
Total (n = 186)E. coli (n = 104)K. pneumoniae (n = 58)P. mirabilis (n = 24)E. coli vs K. pneumoniaeE. coli vs P. mirabilisK. pneumoniae vs P. mirabilis
Patient related
    Males107 (57.5)54 (51.9)40 (69)13 (54.1)0.030.840.20
    Mean age in yr ± SD54 ± 1951 ± 2063 ± 1545 ± 160.010.22<0.001
    Underlying disease
        Solid tumor52 (27.9)21 (20.2)24 (41.4)7 (29.1)0.0040.330.29
        Diabetes50 (26.8)26 (25)20 (34.5)4 (16.7)0.190.380.10
        Hematological malignancy45 (24.2)30 (28.8)12 (20.6)3 (12.5)0.720.090.38
        Liver disease26 (13.9)14 (13.5)9 (15.5)3 (12.5)0.710.900.72
        Chronic renal failure53 (28.4)32 (30.7)21 (36.2)0 (0)0.47<0.001<0.001
    Mean days in the hospital ± SD27 ± 1624 ± 1334 ± 2021 ± 90.010.350.002
    Prior exposure to antimicrobial therapy
        Cephalosporins50 (26.8)25 (24)18 (31)7 (29.2)0.330.600.86
        Quinolones48 (25.8)25 (24)17 (29.3)6 (25)0.460.920.69
        Aminoglycosides19 (10.2)8 (7.7)10 (17.4)1 (4.2)0.060.540.11
        β-Lactam-β-lactamase inhibitors34 (18.3)15 (14.4)11 (18.9)8 (33.3)0.450.030.16
Infection-related
    Health care acquired168 (90.3)92 (88.5)55 (94.8)21 (87.5)0.180.890.24
    Source of infection
        Unknown86 (46.2)41 (39.4)33 (56.9)12 (50)0.030.340.56
        Urinary tract53 (28.4)29 (27.9)15 (25.9)9 (37.5)0.780.350.29
        Pancreatico-biliary tract24 (12.9)19 (18)3 (5.2)2 (8.3)0.020.230.58
        Surgical wound29 (10.7)16 (15.4)2 (3.4)2 (8.3)0.020.370.35
        Lower respiratory tract6 (3.2)1 (1)4 (6.9)1 (4.2)0.030.250.63
        Central venous catheter5 (2.7)4 (3.8)1 (1.7)0 (0)0.450.320.51
  • a All values are presented as “no. (%) of patients” except as noted otherwise in column 1.